Anti-inflammatory and anti-oxidative effects of corilagin in a rat model of acute cholestasis
- Equal contributors
1 Department of Neurosurgery, Neuro-oncology Laboratory, Affiliated Hospital of Jining Medical College, Jining, Shandong, 272029, PR China
2 Liver Disease Center, Department of Infectious Disease, Second Xiangya Hospital, Xiangya Medical School, Central South University, Changsha, 410011, PR China
3 Department of Bioengineering and Therapeutic Sciences, School of Pharmacy, UCSF, CA, 94143, USA
4 Department of Infectious Disease and Hepatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, PR China
5 Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, P.R. China
6 Central Lab, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, P.R. China
Citation and License
BMC Gastroenterology 2013, 13:79 doi:10.1186/1471-230X-13-79Published: 3 May 2013
Nowadays, treatments for cholestasis remain largely nonspecific and often ineffective. Recent studies showed that inflammatory injuries and oxidative stress occur in the liver with cholestasis. In this study, we would use corilagin to treat the animal model of acute cholestasis in order to define the activity to interfere with inflammation-related and oxidative stress pathway in cholestatic pathogenesis.
Rats were administrated with alpha-naphthylisothiocyanate to establish model of cholestasis and divided into corilagin, ursodeoxycholic acid, dexamethasone, model and normal groups with treatment of related agent. At 24h, 48h and 72h time points after administration, living condition, serum markers of liver damage, pathological changes of hepatic tissue, nuclear factor (NF)-kappaB, myeloperoxidase (MPO), malondialdehyde (MDA), superoxide dismutase (SOD) and nitric oxide (NO) were examined and observed.
Compared to model group, corilagin had remarkable effect on living condition, pathological manifestation of liver tissue, total bilirubin, direct bilirubin, (P<0.01), but no effect on alanine aminotransferase (ALT) and aspartate aminotransferase (AST). With corilagin intervention, levels of MPO, MDA and translocation of NF-κB were notably decreased, and levels of SOD and NO were markedly increased (P<0.05 or P<0.01).
It is shown that corilagin is a potential component to relieve cholestasis through inflammation-related and oxidation-related pathway.